Respirion is developing a novel inhaled antibiotic therapy that combines an inhaled version of an approved metal‑chelating drug with the antibiotic tobramycin in a new formulation and delivery device. The therapy uses an adjuvant to break down bacterial biofilms and in a clinical study produced a 400‑fold reduction in bacterial load and an average 16% improvement in lung function versus 5% with tobramycin alone. The technology was incubated at the Telethon Kids Institute and the product was tested in collaboration with the Western Australian Department of Health. MRCF BTF has committed up to AU$20M in stages to support larger clinical studies and commercial validation. The Cystic Fibrosis Foundation has committed up to US$3M and will coordinate clinical studies through its Therapeutics Development Network. Respirion plans to advance larger trials under FDA regulations in the US and Australia to further validate the therapy's potential to improve infection control and lung function in CF patients.

Total raised

$14M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2019